Endocrine Adverse Events Induced by Cancer Treatments: The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography
Open Access
Abstract
Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy, substantially improving survival across a broad range of malignancies. However, these agents are associated with a unique profile of endocrine immune-related adverse events (irAEs), including thyroiditis, hypophysitis, adrenalitis, and pancreatitis, which differ significantly from the toxicities seen with conventional chemotherapy. These complications often arise unpredictably during treatment and may result in irreversible hormone deficiencies requiring lifelong replacement, underscoring the importance of early detection. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has emerged as a valuable tool not only for oncologic staging and response assessment but also for detecting metabolic changes in endocrine organs. PET/CT can identify irAEs before the appearance of clinical symptoms or biochemical abnormalities. Emerging evidence suggests that the presence of endocrine irAEs identified by 18F-FDG PET/CT may correlate with improved treatment response and survival, possibly reflecting enhanced immune activation. This comprehensive review discusses the role of 18F-FDG PET/CT in the early recognition of therapy-induced endocrine toxicities, facilitating timely intervention through hormone replacement or immunosuppressive therapy while minimizing unnecessary treatment interruptions. Effective integration of metabolic imaging with clinical and laboratory evaluation requires coordinated multidisciplinary collaboration among oncologists, endocrinologists, and nuclear medicine physicians to optimize outcomes and reduce endocrine-related morbidity in the era of precision oncology.Keywords
This publication has 47 references indexed in Scilit:
- Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [18F]FDG PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patientHormones, 2024
- Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2022
- Effets secondaires endocriniens de la radiothérapie : diagnostic, prévention et traitementsCancer/Radiothérapie, 2022
- Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologistsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)Journal of Endocrinological Investigation, 2018
- Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusionsAnnales d'Endocrinologie, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- New Imaging Methods for Detection of Drug-Induced Cardiotoxicity in Cancer PatientsCurrent Cardiovascular Imaging Reports, 2017